A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2020-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with
platinum-resistant or refractory recurrent ovarian cancer.